欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
本课题建立吗啡,甲基苯丙胺以及可卡因诱导的大、小鼠行为敏化模型.探讨了L-型钙通道阻滞剂,情绪稳定剂（锂盐,丙戊酸钠和卡马西平）,以及新型μ受体部分激动剂噻吩诺啡对行为敏化形成,转化以及表达的影响.利用行为敏化模型,率先开展了曲马朵和槟榔嚼块提取物多药滥用的精神药理学研究.此外,在条件性位置偏爱和纳洛酮促吗啡戒断动物模型上,发现钙调蛋白抑制剂具有明显的干预作用,钙调蛋白可能是阿片类物质依赖治疗的新的分子靶点.与澳大利亚成瘾神经科学的合作研究发现,GABAB受体正性别构调节剂CGP9730可以抑制嗜酒大鼠的自饮酒行为,具有潜在的治疗酒精依赖与成瘾的临床应用价值.
英文摘要：
In our studies, the behavioral sensitization animal models, including rats and mice, induced by morphine, methamphetamine or cocaine were established to investigate the effects of L - type calcium channel antagonists, mood stablers （lithium salts, valproate, and carbamazepine）, and a novel mu - receptor partial agonist the morphine on development, transfer, and expression of behavioral sensitization. Using behavioral sensitization animal models, poly - drug abuse about tramadol and betel quid extract was investigated in psychopharmacological profiles. Furthermore, our data indicate that calmodulin inhibitors could reduce rewarding effects in morphine -induced conditioned place preference （CPP） and inhibit naloxone - precipitated withdrawal symptoms in morphine - dependent rats and mice, suggesting that calmodulin may be a novel molecular target for intervening opioids abuse and addiction. A Sino -Australian collaboration in addiction neuroscience has demonstrated that GABAB receptor positive allosteric modulator CGP7930, like baclofen, can reduce operant self- administration of ethanol in alcohol -preferring rats, which may be of intervening potential to alcohol abuse and addiction in clinic.
同期刊论文项目
同项目期刊论文
位置：